Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Gilead Sciences, Inc.'s quarterly P/E stands at 21.6x, down 19.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has expanded 49.4% YoY to 20.1x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.25 | 21.64 | 17.64 | 11.42 | 17.77 | 26.94 | 16.26 | 20.96 | 13.30 | — | 17.77 | 10.83 | 23.21 |
| — | -19.7% | +8.4% | -45.5% | +33.6% | — | -8.5% | +93.5% | -42.7% | — | +7.6% | -0.3% | +36.7% | |
| P/S Ratio | 5.22 | 6.28 | 4.85 | 4.48 | 4.91 | 5.29 | 3.84 | 3.48 | 3.09 | 3.42 | 3.58 | 3.34 | 3.67 |
| — | +18.7% | +26.3% | +28.6% | +59.2% | +54.9% | +7.4% | +4.3% | -16.0% | -17.1% | -2.6% | +21.0% | +18.1% | |
| P/B Ratio | 6.87 | 7.46 | 6.80 | 6.49 | 7.10 | 7.39 | 6.04 | 5.72 | 4.72 | 5.23 | 4.47 | 4.24 | 4.60 |
| — | +0.9% | +12.5% | +13.5% | +50.6% | +41.3% | +35.1% | +35.0% | +2.6% | +4.7% | -12.6% | +14.6% | +19.3% | |
| P/FCF | 16.25 | 18.00 | 12.32 | 8.79 | 48.31 | 21.34 | 10.28 | 6.31 | 17.96 | 10.80 | 13.02 | 14.42 | 11.02 |
| — | -15.6% | +19.8% | +39.3% | +169.1% | +97.5% | -21.0% | -56.3% | +62.9% | -32.5% | +14.5% | +100.7% | -6.1% | |
| EV / EBITDA | 11.80 | 20.13 | 11.62 | 9.77 | 12.55 | 13.48 | 10.62 | 19.54 | 7.97 | — | 13.19 | 8.58 | 12.41 |
| — | +49.4% | +9.4% | -50.0% | +57.5% | — | -19.5% | +127.8% | -35.8% | — | +14.9% | +17.3% | +27.6% | |
| EV / EBIT | 14.59 | 20.13 | 18.30 | 10.06 | 14.81 | 20.70 | 13.83 | 25.83 | 11.62 | — | 15.92 | 11.13 | 16.02 |
| — | -2.8% | +32.4% | -61.1% | +27.5% | — | -13.2% | +132.1% | -27.5% | — | +12.0% | +20.4% | +12.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Gilead Sciences, Inc.'s operating margin was 37.2% in Q1 2026, down 0.6 pp QoQ and up 3.6 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 38.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 3.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.8% | 79.2% | 79.5% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% | 77.8% | 76.8% | 70.6% | 77.8% | 78.1% |
| — | +3.0% | +0.5% | +0.8% | +1.3% | +0.1% | +12.0% | +1.7% | -0.5% | -1.5% | -12.9% | -3.0% | +1.5% | |
| Operating Margin | 39.7% | 37.2% | 37.7% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% | 38.0% | -64.6% | 22.7% | 37.2% | 25.2% |
| — | +10.7% | +16.4% | +263.9% | -8.1% | +151.9% | +43.0% | -68.4% | +50.7% | -340.8% | -26.1% | -7.6% | -22.2% | |
| Net Margin | 28.9% | 29.0% | 27.5% | 39.3% | 27.7% | 19.7% | 23.6% | 16.6% | 23.2% | -62.4% | 20.1% | 30.9% | 15.8% |
| — | +47.2% | +16.9% | +136.6% | +19.2% | +131.6% | +17.3% | -46.3% | +46.6% | -492.2% | -9.5% | +21.7% | -13.3% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.7% | 8.8% | 9.9% | 14.9% | 10.1% | 6.9% | 9.5% | 6.8% | 9.1% | -20.7% | 6.4% | 10.1% | 5.0% |
| — | +27.9% | +4.5% | +117.1% | +12.0% | +133.1% | +49.2% | -31.9% | +82.1% | -532.8% | -18.1% | +16.1% | -12.8% | |
| ROA | 14.4% | 3.5% | 3.7% | 5.3% | 3.5% | 2.3% | 3.1% | 2.3% | 2.9% | -7.0% | 2.3% | 3.5% | 1.7% |
| — | +53.9% | +18.2% | +130.5% | +19.0% | +132.4% | +36.8% | -33.7% | +74.6% | -536.0% | -12.0% | +22.6% | -7.4% | |
| ROIC | 23.2% | 5.0% | 5.7% | 6.4% | 4.9% | 4.6% | 5.0% | 1.8% | 5.2% | -8.1% | 2.9% | 4.8% | 3.1% |
| — | +8.2% | +13.3% | +259.9% | -4.9% | +157.2% | +74.3% | -63.1% | +69.5% | -359.9% | -29.9% | -6.3% | -16.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Gilead Sciences, Inc.'s Debt/EBITDA ratio is 9.4x, up from 6.7x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 43.7% YoY to 1.97x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.09 | 0.95 | 1.09 | 1.16 | 1.27 | 1.31 | 1.42 | 1.26 | 1.28 | 1.44 | 1.13 | 1.12 | 1.20 |
| — | -27.6% | -23.4% | -8.1% | -0.8% | -9.4% | +25.9% | +12.6% | +7.2% | +19.7% | -5.2% | -6.2% | -7.7% | |
| Debt / EBITDA | 1.70 | 9.43 | 6.69 | 6.22 | 7.88 | 8.51 | 8.69 | 14.73 | 7.00 | — | 11.16 | 7.55 | 10.76 |
| — | +10.9% | -23.0% | -57.8% | +12.7% | — | -22.1% | +95.0% | -35.0% | — | +23.6% | +0.7% | +4.8% | |
| Current Ratio | 1.68 | 1.97 | 1.68 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 | 1.43 | 1.34 | 1.02 |
| — | +43.7% | +5.4% | +15.3% | +15.1% | +26.9% | +12.0% | -5.8% | +11.7% | -15.6% | +11.0% | +2.9% | -28.4% | |
| Quick Ratio | 1.31 | 1.77 | 1.31 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 | 1.27 | 1.20 | 0.91 |
| — | +43.9% | -9.7% | +18.8% | +20.7% | +31.0% | +14.8% | -8.1% | +5.3% | -17.0% | +10.1% | +3.3% | -28.5% | |
| Interest Coverage | 10.57 | 9.80 | 9.15 | 15.22 | 10.56 | 7.34 | 9.70 | 5.02 | 9.66 | -16.66 | 7.56 | 10.99 | 7.90 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into GILD consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GILD stock.
Gilead Sciences, Inc.'s current P/E is 18.3x. The average P/E over the last 4 quarters is 17.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Gilead Sciences, Inc.'s current operating margin is 39.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Gilead Sciences, Inc.'s business trajectory between earnings reports.